GMDN (Global Medical Device Nomenclature) beset by pricing challenges
This article was originally published in Clinica
Marketing the Global Medical Device Nomenclature, the recently available worldwide medical device naming system (see Clinica No 985, p 10) is proving a challenging task for those responsible for ensuring that the system has enough funding to be maintained and updated.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.